- Stocks
- Pharma & Healthcare
- Piramal Phytoca
Piramal Phytoca share price
NSE: PIRPHYTOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Piramal Phytoca at a glance
With a market capitalisation of ₹21,083 Cr, it ranks 343rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY19.
Key numbers
- Market cap
- ₹21,083 CrRank 343 on NSE
- Price to book
- -3.69×FY19
- ROE
- 0.0%FY19
- ROCE
- 29.5%FY19
- Debt to equity
- -0.53FY19
- Net profit margin
- −32.8%FY19
- Book value / share
- −₹9.84FY19
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Piramal Phytoca financials
| Item | FY14 | FY15 | FY16 | FY17 | FY18 | FY19 |
|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹24 Cr | ₹25 Cr |
| Operating profit | −₹4 Cr | −₹3 Cr | −₹3 Cr | ₹0 Cr | −₹22 Cr | −₹8 Cr |
| Net profit | −₹4 Cr | −₹3 Cr | −₹3 Cr | ₹0 Cr | −₹22 Cr | −₹8 Cr |
| EPS (₹) | −₹1.60 | −₹1.30 | −₹1.27 | ₹0.07 | −₹8.65 | −₹3.17 |
| Cash from operations | ₹1 Cr | ₹0 Cr | ₹2 Cr | −₹0 Cr | −₹1 Cr | −₹14 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹12 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | −₹17 Cr | −₹26 Cr |
Piramal Phytoca vs peers
The listed Pharma & Healthcare companies nearest to Piramal Phytoca by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NEULANDLABNeuland Laboratories | ₹18,855.00 | −0.45% | +16.3% | ₹24,191 Cr | 66.3 | — |
| RUBICONRubicon Research | ₹1,408.90 | −3.57% | — | ₹23,301 Cr | 92.3 | — |
| PGHHProcter Gamble | ₹6,856.00 | −0.36% | −51.5% | ₹22,255 Cr | 26 | — |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹44.78 | +1.08% | +0.9% | ₹20,963 Cr | 22.6 | — |
| GRANULESGranules India | ₹807.65 | +0.04% | +41.9% | ₹20,013 Cr | 33 | — |
| IGLIndraprastha | ₹141.87 | −0.11% | −33.1% | ₹19,862 Cr | 12.8 | — |
Ask anything about Piramal Phytoca
Pivot answers on the live chart with evidence you can check, and tests strategies against PIRPHYTO's own history. Try: “Why has PIRPHYTO moved over the last three months?” · “Backtest a 50-day moving-average crossover on PIRPHYTO over five years” · “Compare PIRPHYTO with NEULANDLAB on margins and valuation”
Frequently asked questions about Piramal Phytoca
What is the market cap of Piramal Phytoca?
Piramal Phytoca's market capitalisation is ₹21,083 Cr (₹21,083 Cr) at the 22 Oct 2026 close, ranking 343rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Piramal Phytoca?
Return on equity was 0.0% in FY19 and return on capital employed was 29.5% in FY19 (standalone figures).
Is Piramal Phytoca a debt-free company?
Piramal Phytoca is close to debt-free: its debt-to-equity ratio was -0.53 in FY19.
Who are Piramal Phytoca's competitors?
The listed Pharma & Healthcare companies closest to Piramal Phytoca by market cap are Neuland Laboratories, Rubicon Research, Procter Gamble, SAGILITY, Granules India and Indraprastha.
Is Piramal Phytoca a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Piramal Phytoca's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PIRPHYTO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text